Clinical trials referenced in this document:
Funding for this research was provided by:
national institute of mental health (R01MH069801)
Received: 27 July 2021
Accepted: 18 January 2022
First Online: 2 March 2022
: The Institutional Review Boards of the University of Texas Southwestern Medical Center and the Stanford University School of Medicine approved this study. All participants provided written informed consent.
: Not applicable.
: TS in the past 36 months has reported grants from Pathway Genomics, Stanley Medical Research Institute, Elan Pharma International Limited, Merck and Co., and Sunovion Pharmaceuticals; consulting fees from Allergan, Impel NeuroPharma Inc., Intraceluular Therapies, and Sunovion Pharmaceuticals; honoraria from CME Institute, Health and Wellness Partners Inc., and CMEology; royalties from Wolters Kluwer Health (UpToDate), Jones and Bartlett, American Psychiatric Association Press, and Hogrefe Publishing. MO in the past 36 months has reported consulting fees from Johnson & Johnson, Sage Therapeutics, and Alkermes; and grant support from Palo Alto Health Sciences, Inc. VC in the past 36 months has reported grants from the National Cancer Institute and royalties from UpToDate. SA, IG, and GF declare that they have no competing interests.